Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

shYAP1 # 1 Citations (15)

Originally described in: beta-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis.
Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, Shao DD, Schumacher SE, Weir BA, Vazquez F, Cowley GS, Root DE, Mesirov JP, Beroukhim R, Kuo CJ, Goessling W, Hahn WC Cell. 2012 Dec 21;151(7):1457-73. doi: 10.1016/j.cell.2012.11.026. Epub 2012 Dec 13.
PubMed Journal

Articles Citing shYAP1 # 1

A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells. Ramesh M, Krishnan N, Muthuswamy SK, Tonks NK. J Biol Chem. 2015 Apr 10;290(15):9646-59. doi: 10.1074/jbc.M114.627968. Epub 2015 Feb 13. PubMed
TAZ and YAP are frequently activated oncoproteins in sarcomas. Fullenkamp CA, Hall SL, Jaber OI, Pakalniskis BL, Savage EC, Savage JM, Ofori-Amanfo GK, Lambertz AM, Ivins SD, Stipp CS, Miller BJ, Milhem MM, Tanas MR. Oncotarget. 2016 May 24;7(21):30094-108. doi: 10.18632/oncotarget.8979. PubMed
A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells. Qu L, Wu Z, Li Y, Xu Z, Liu B, Liu F, Bao Y, Wu D, Liu J, Wang A, Chu X, Sun Y, Chen C, Zhang Z, Wang L. Nat Commun. 2016 Nov 25;7:12692. doi: 10.1038/ncomms12692. PubMed
A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y, Zhang Y, Han X, Liu S, Cheng K, Zhao Y, Shi J, Guo J, Hao J, Ren H, Nie G. Cancer Lett. 2017 Aug 28;402:61-70. doi: 10.1016/j.canlet.2017.05.015. Epub 2017 May 30. PubMed
A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Mello SS, Valente LJ, Raj N, Seoane JA, Flowers BM, McClendon J, Bieging-Rolett KT, Lee J, Ivanochko D, Kozak MM, Chang DT, Longacre TA, Koong AC, Arrowsmith CH, Kim SK, Vogel H, Wood LD, Hruban RH, Curtis C, Attardi LD. Cancer Cell. 2017 Oct 9;32(4):460-473.e6. doi: 10.1016/j.ccell.2017.09.007. PubMed
Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. Sulaiman A, McGarry S, Li L, Jia D, Ooi S, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Gadde S, Li X, Wang L. Mol Oncol. 2018 Apr;12(4):423-440. doi: 10.1002/1878-0261.12167. Epub 2018 Feb 21. PubMed
Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Melhuish TA, Kowalczyk I, Manukyan A, Zhang Y, Shah A, Abounader R, Wotton D. Biochim Biophys Acta Gene Regul Mech. 2018 Nov;1861(11):983-995. doi: 10.1016/j.bbagrm.2018.10.005. Epub 2018 Oct 10. PubMed
The mitochondrial deoxyguanosine kinase is required for cancer cell stemness in lung adenocarcinoma. Lin S, Huang C, Sun J, Bollt O, Wang X, Martine E, Kang J, Taylor MD, Fang B, Singh PK, Koomen J, Hao J, Yang S. EMBO Mol Med. 2019 Oct 21:e10849. doi: 10.15252/emmm.201910849. PubMed
Sestrin2 inhibits YAP activation and negatively regulates corneal epithelial cell proliferation. Lee JS, Park HW, Cho KJ, Lyu J. Exp Mol Med. 2020 Jun;52(6):951-962. doi: 10.1038/s12276-020-0446-5. Epub 2020 Jun 12. PubMed
YAP1 regulates chondrogenic differentiation of ATDC5 promoted by temporary TNF-alpha stimulation through AMPK signaling pathway. Chen P, Yang B, Wu Y, Wang J. Mol Cell Biochem. 2020 Nov;474(1-2):209-218. doi: 10.1007/s11010-020-03846-z. Epub 2020 Aug 3. PubMed
The Hippo Pathway Effector YAP1 Regulates Intestinal Epithelial Cell Differentiation. Fallah S, Beaulieu JF. Cells. 2020 Aug 13;9(8). pii: cells9081895. doi: 10.3390/cells9081895. PubMed
Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration. Uneda A, Kurozumi K, Fujimura A, Fujii K, Ishida J, Shimazu Y, Otani Y, Tomita Y, Hattori Y, Matsumoto Y, Tsuboi N, Makino K, Hirano S, Kamiya A, Date I. Acta Neuropathol Commun. 2021 Feb 22;9(1):29. doi: 10.1186/s40478-021-01124-7. PubMed
USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization. Wei Y, Jiang Z, Lu J. Oncol Lett. 2021 May;21(5):394. doi: 10.3892/ol.2021.12655. Epub 2021 Mar 18. PubMed
Src family kinases inhibit differentiation of intestinal epithelial cells through the Hippo effector YAP1. Fallah S, Beaulieu JF. Biol Open. 2021 Nov 15;10(11). pii: 272600. doi: 10.1242/bio.058904. Epub 2021 Nov 15. PubMed
Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip. Cui H, Sun X, Schilling M, Herold-Mende C, Reischl M, Levkin PA, Popova AA, Turcan S. Adv Healthc Mater. 2023 May 10:e2300591. doi: 10.1002/adhm.202300591. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.